Ionis To Get Head Start On Arrowhead With Tryngzola Launch

The antisense oligonucleotide specialist is ready to launch its rare disease therapy Tryngzola but could face competition from a more potent rival by mid-2025.

Ionis HQ
Roche will lead the Phase III development of the therapy, based on Ionis' antisense drug platform. • Source: Ionis

More from New Products

More from Scrip